Osang Healthcare Develops COVID-19 Diagnostic Kit... Launches Sales in Overseas Markets

[Asia Economy Reporter Oh Ju-yeon] Osang Healthcare, an affiliate of Osang Jaiel, a company listed on the KOSDAQ, announced on the 24th that it has completed the development of a novel coronavirus (COVID-19) diagnostic kit and is starting sales in overseas markets.

Osang Healthcare explained that its COVID-19 diagnostic kit, 'GeneFinder™ COVID-19 Plus RealAMP Kit,' is a product that qualitatively detects three target genes of COVID-19 (E Gene, RdRp Gene, N Gene), and that it has applied for emergency use authorization from the Korea Disease Control and Prevention Agency, with the review currently underway.

They added that they have received an order for 5,000 tests from Elitek, a global diagnostic reagent and equipment company headquartered in Italy, and plan to ship 10,000 tests in March.

An Osang Healthcare official stated, "In addition, prototype testing and delivery negotiations are being specifically conducted with countries in Asia and the Middle East, including India, Iran, Malaysia, the Philippines, and Vietnam, so we expect significant sales expansion starting in March."

Osang Healthcare is a listed company registered on the K-OTC market, supplying rapid diagnostic kits for Influenza A and B, which are used in major hospitals and clinics nationwide in Korea. In January, during the flu season, approximately 800,000 tests of Osang Healthcare's rapid flu diagnostic kits were sold.

This content was produced with the assistance of AI translation services.